Clinical Overview
Tolterodine Tartrate Extended-Release Capsules (2mg, 4mg) is a competitive muscarinic receptor antagonist on the WHO Model List framework for Overactive Bladder. It targets muscarinic M2 and M3 receptors in the urinary bladder with functional organ selectivity over salivary glands, suppressing involuntary detrusor contractions while allowing normal voluntary voiding. Indicated for treatment of Overactive Bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily, 4 mg once daily (or 2 mg once daily in patients with hepatic impairment or taking CYP3A4 inhibitors) with water. Swallow the extended-release capsule whole; do not chew or crush. Can be taken with or without food.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dry mouth, headache, constipation, dry eyes, dizziness, abdominal pain, dyspepsia. Rare/Severe: Acute urinary retention, severe hypersensitivity reactions, and QT interval prolongation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma. CYP2D6 and CYP3A4 substrate; reduce dose with ketoconazole, itraconazole, or clarithromycin.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.
Tamsulosin Hydrochloride 0.4mg + Tolterodine Tartrate 2mg Extended Release Capsules
Tamsulosin Hydrochloride (0.4mg) and Tolterodine Tartrate (2mg/4mg Extended Release) Capsules is a fixed-dose combination for men suffering from mixed storage and voiding lower urinary tract symptoms (LUTS). Tamsulosin relieves voiding symptoms (hesitancy, weak stream, straining) via alpha-1A adrenergic blockade, while tolterodine competitively antagonizes muscarinic M2/M3 receptors in the detrusor muscle, abolishing involuntary bladder spasms and relieving storage symptoms (frequency, urgency, nocturia). Indicated for men with BPH and co-existing Overactive Bladder (OAB).
Tamsulosin Hydrochloride 0.4mg + Tolterodine Tartrate 4mg Extended Release Capsules
Tamsulosin Hydrochloride (0.4mg) and Tolterodine Tartrate (2mg/4mg Extended Release) Capsules is a fixed-dose combination for men suffering from mixed storage and voiding lower urinary tract symptoms (LUTS). Tamsulosin relieves voiding symptoms (hesitancy, weak stream, straining) via alpha-1A adrenergic blockade, while tolterodine competitively antagonizes muscarinic M2/M3 receptors in the detrusor muscle, abolishing involuntary bladder spasms and relieving storage symptoms (frequency, urgency, nocturia). Indicated for men with BPH and co-existing Overactive Bladder (OAB).
Tolterodine Tartrate Extended Release Capsules 4 mg
Tolterodine Tartrate Extended-Release Capsules (2mg, 4mg) is a competitive muscarinic receptor antagonist on the WHO Model List framework for Overactive Bladder. It targets muscarinic M2 and M3 receptors in the urinary bladder with functional organ selectivity over salivary glands, suppressing involuntary detrusor contractions while allowing normal voluntary voiding. Indicated for treatment of Overactive Bladder with symptoms of urge urinary incontinence, urgency, and frequency.